Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...

Eli Lilly’s revenue was further bolstered by Mounjaro, its blockbuster diabetes drug. Mounjaro’s sales soared to $2.21 billion for the quarter, a dramatic increase from $279.2 million in the ...

As Eli Lilly continues to elevate the profile of its popular GLP-1 drug Mounjaro, the drugmaker has found a partner — or two — to support the mission. Lilly recently unveiled a paid partnership with ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro.

Eli Lilly has filed lawsuits against four telehealth companies it says are selling compounded versions of Mounjaro, Lilly’s diabetes drug, and Zepbound, a drug for weight loss and control.

Mounjaro, a once-weekly injection approved by India’s drug regulator, is priced at Rs4,375 ($50.86) for a 5milligram vial and Rs3,500 for a 2.5mg vial, its lowest doses, the company said. Its ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Mounjaro and Zepbound are by far Lilly's fastest-growing businesses, and the company's momentum in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days.